ePRO provider Symfo will now offer technology transfer capabilities with its new product Artist. This new product is a user-friendly tool that allows customers to build and deploy their own ePRO studies on demand.
Users have the option to start with Symfo's full-service offering and migrate to Artist when ready, or to begin using it from the very first study. Artist was designed with simplicity in mind to benefit Data Managers, CRAs, and Clinical Assistants. Programming skills are not necessary and a basic knowledge of the MS Office suite is sufficient, according to the company.
Artist may be accessed locally or through an Internet connection. Designers start by defining the general parameters such as name and languages of the study using a configuration panel. The next step is to design each PDA screen with edit checks and logic. Artist offers a drag and drop interface that is intended to make this step straightforward, including importing translations if necessary. Once all designing is completed, users have the ability to test the application in a built-in emulator. The application is then installed on the PDAs and will launch automatically.
Artist is available on a subscription pay-as-you-go basis, either as a stand-alone product or as part of a turn-key bundled package. Visit the company's Web site for more information on this product, www.symfo.com.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.